A Phase 1 interventional study of PF-07054894 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-12.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the safety, tolerability, and PK of single escalating doses and multiple escalating doses of PF-07054894.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single or multiple ascending doses of oral PF-07054894
Drug: PF-07054894
Participants will receive matching placebo
Drug: Placebo
Participants will receive oral ascending doses
Participants will receive matching placebo
AEs following Single ascending dose (SAD)
Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs
Time frame: Day 1 up to Day 28 (SAD)
AEs following multiple ascending dose (MAD)
Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs
Time frame: Day 1 up to Day 42 (MAD)
Percentage of subjects with laboratory abnormalities
Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)
Number of subjects with change from baseline in vital signs
Number of subjects with change from baseline of blood pressure, pulse rate, and oral temperature
Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)
Number of subjects with change from baseline in electrocardiogram (ECG) parameters
Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)
Maximum Plasma concentration (Cmax)
Maximum observed plasma concentration (Cmax)
Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)
Time to reach plasma Cmax (Tmax)
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 up to Day 3 (SAD)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).
Time frame: Day 1 up to Day 3 (SAD)
Dose normalized Cmax (Cmax(dn))
Dose normalized maximum plasma concentration (Cmax(dn))
Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)
Apparent Oral Clearance (CL/F)
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed and a quantitative measure of the rate at which the drug is removed from the blood.
Time frame: Day 1 (SAD) or Day 14 (MAD)
Apparent Volume of Distribution (Vz/F)
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Day 1 (SAD) or Day 14 (MAD)
Single dose and Multiple Dose PK half-life (t½)
Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 (SAD) or Day 14 (MAD)
Observed Accumulation Ratio for Cmax (Rac,Cmax)
Accumulation ratio based on maximum plasma concentration (Cmax) calculated as: Rac,Cmax = Cmax at steady state (ss) divided by Cmax at first dose.
Time frame: MAD, Day 14
Observed Accumulation Ratio for AUCτau (Rac, AUCτau)
Accumulation ratio calculated as, Rac obtained from Area Under the Concentration Time Curve (AUCτau) from time 0-τau (Day 14) divided by AUC from time 0-τau (Day 1).
Time frame: MAD, Day 14
Area Under the Curve From Time Zero to End of Dosing Interval (AUCτau)
Area under the concentration curve from time 0 to end of dosing interval (AUCτau), where dosing interval is 12 hours.
Time frame: Day 1 and Day 14 of MAD
Minimum Observed Plasma Trough Concentration (Cmin)
Minimum plasma concentration over the dosing interval τau (12 hour) from first dose to last dose
Time frame: Day 1 up to Day 14 of MAD
Multiple dose PK/AUCτau (dn)
Dose normalized area under the curve over the dosing interval τau (12 hour) after the first and last dose (AUCτau (dn))
Time frame: Day 1 and Day 14 of MAD
Cumulative Amount of Drug Recovered Unchanged in Urine during dosing interval (Ae,τau)
Cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval is 12 hours (Ae,τau)
Time frame: MAD, Day 14
Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τau (Ae,τau%)
Percent of dose recovered in urine as unchanged drug over the dosing interval (Ae,τau%)
Time frame: MAD, Day 14
Renal Clearance (Clr)
Renal clearance calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae,τau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτau), where dosing interval is 12 hours.
Time frame: MAD, Day 14
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Jun 2022, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-07054894